MedTrace Logo

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

NCT00237666 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-06-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.

Conditions

  • Bipolar II Disorder
  • Major Depressive Episode

Interventions

DRUG

Ziprasidone

Ziprasidone 20-60 mg BID, taken orally.

Sponsors & Collaborators

  • Liebowitz, Michael R., M.D.

    collaborator INDIV

  • Pfizer

    collaborator INDUSTRY

  • The Medical Research Network

    lead OTHER

Principal Investigators

  • Michael R Liebowitz, MD · Medical Research Network, L.L.C.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00237666 on ClinicalTrials.gov